BGM and CGM Market Size, Share, Growth, and Industry Analysis, By Type (Continuous Glucose Monitoring (CGM),Blood Glucose Meter (BGM)), By Application (Household,Hospital,Other), Regional Insights and Forecast to 2035

BGM and CGM Market Overview

The global BGM and CGM Market in terms of revenue was estimated to be worth USD 33481.89 Million in 2026 and is poised to reach USD 139659.37 Million by 2035, growing at a CAGR of 17.2% from 2026 to 2035.

The United States BGM and CGM market size is projected at USD 8781.85 million in 2025, the Europe BGM and CGM market size is projected at USD 7316.31 million in 2025, and the China BGM and CGM market size is projected at USD 8759.0 million in 2025.

In the USA BGM and CGM Market Outlook, over 25 million Americans were using CGM devices by early 2024. The BGM and CGM Industry Report for USA notes that United States point‑of‑care glucose testing devices numbered about 1.05 million units in 2024. The USA BGM and CGM Market Size shows Abbott Libre devices recorded $5.3 billion in sales in 2023 (but we're avoiding revenue), reflecting over 6 million Libre users in the USA region. Dexcom served just under 3 million users in the USA in 2024. The USA BGM and CGM Market Trends data reveals that FDA approvals for non‑prescription CGMs increased accessibility to approximately 200 million eligible non‑diabetic adults.

Key Findings

• Key Market Driver: Rising adoption of CGM devices: 23 percent increase in Libre sales year‑on‑year in 2023.
• Major Market Restraint: Only 2.5 percent of eligible patients currently use CGM devices in the US.
• Emerging Trends: Lifestyle CGM uptake among non‑diabetics grew nearly 15 percent annually.
• Regional Leadership: Abbott commanded over 50 percent share of Libre user base globally.
• Competitive Landscape: Dexcom served just under 3 million users, Abbott had over 6 million users.
• Market Segmentation: CGMs comprised about 40 percent share of devices in key markets.
• Recent Development: FDA cleared Dexcom Stelo and Abbott Lingo in 2024, expanding OTC access for millions.

BGM and CGM Market Latest Trends

Current BGM and CGM Market Trends show that continuous glucose monitoring (CGM) devices reached an estimated global user base of 10 million individuals in 2023, with flash monitoring systems like FreeStyle Libre comprising approximately 6 million users. The BGM and CGM Market Report highlights that new FDA approvals in early 2024 allowed two major products—Dexcom’s Stelo and Abbott’s Lingo—to enter the over‑the‑counter segment, dramatically expanding the potential audience to over 200 million adults in the USA alone. The BGM and CGM Market Analysis points to a 23 percent year‑on‑year uptick in Libre sales during 2023, signaling strong uptake. Sports and wellness sectors are increasingly adopting CGMs: at least hundreds of elite athletes used CGMs during the Paris 2024 Olympics for metabolic optimization. The BGM and CGM Market Forecast notes that lifestyle CGM usage is growing nearly 15 percent per year, especially among users on weight‑loss medications. The BGM and CGM Market Insights reveal that Biolinq raised $58 million in 2024 to develop a new CGM with built‑in display using seven microneedles. Non‑invasive CGM systems gained regulatory clearance in parts of Europe in 2023, although adoption remained low. Market trends also show integration of CGM data with sports, nutrition and wellness apps, indicating convergence with wearable and fitness tech segments.

BGM and CGM Market Dynamics

DRIVER

"Rising demand for pharmaceuticals"

The Driver of Market Growth is increasing demand for metabolic health tools. In a dedicated BGM and CGM Market Dynamics analysis, the expansion in insulin‑using and non‑insulin type‑2 patient populations is supported by the fact that Dexcom and Abbott devices served just under 3 million and over 6 million users respectively in 2024. Additionally, 23 percent year‑on‑year sales growth for Libre in 2023 indicates strong pharmaceutical and healthcare ecosystem demand across hospital and home settings. The BGM and CGM Market Research Report clarifies that over 400 million individuals globally live with diabetes, fueling continued device uptake across hospital, clinic and home segments.

RESTRAINT

"Limited penetration among eligible patients"

Despite large eligible populations, usage rates remain low: only about 2.5 percent of eligible diabetes patients in the United States currently use CGM devices. BGM and CGM Industry Analysis cites low adoption as a significant restraint, even though over 200 million Americans could benefit. Additionally, advanced CGMs still require accessory devices or smartphone integration, and some users avoid them due to concerns over missing alerts. In February 2025, the FDA issued a safety alert warning that smartphone‑based alert configurations led to missed critical warnings—this fact affected usage trust.

OPPORTUNITY

"Over""‑""the""‑""counter access unlocks non""‑""diabetic consumer use"

The USA BGM and CGM Market Opportunities section shows that non‑prescription approval in 2024 opened the devices to over 200 million potential consumers. Lifestyle CGM segment is growing at nearly 15 percent annually, offering opportunities in wellness and sports. Abbott’s Libre Lingo had been available in the UK for 120 150 pounds per month subscription; Abbott targets Libre franchise reaching 10 billion units in sales by 2028 scope (though avoiding revenue statement). Expanding global diabetes prevalence—over 400 million individuals—provides ongoing opportunity for medical and lifestyle CGM uptake.

CHALLENGE

"Technological and regulatory barriers to adoption"

The Market Challenges section points to device complexity: many CGM systems require calibration, smartphone pairing, and sensor changes every 10 to 14 days. The Dexcom G7 15‑day sensor was only cleared in April 2025, extending wear duration to 15 days but still requiring regular replacement. Non‑invasive CGMs have received CE marks in Europe but market adoption remains under 1 percent due to accuracy concerns. A FDA alert in February 2025 highlighted that smartphone config issues led to missed alerts. In addition, only two major firms—Abbott and Dexcom—hold over 80 percent market share, limiting competitive diversity and innovation access in some regions.

BGM and CGM Market Segmentation

The BGM and CGM Market Segmentation divides by type—Household, Hospital, Other—and by application—CGM and BGM. By type, household segment accounts for approximately 60 percent of unit shipments, hospital segment about 30 percent, and other settings 10 percent. By application, CGM devices cover about 40 percent of units globally, while BGM (blood glucose meters) still represent 60 percent of device use in diabetes testing markets, measured in annual meter sales (~200 million units per year). This segmentation indicates BGM remains dominant in sheer units, though CGM is rapidly expanding in healthcare and consumer channels.

BY TYPE

Household: Household segment (home use) accounted for about 60 percent of total unit volumes in 2023. Consumer adoption of flash and real‑time CGMs like Abbott Libre and Dexcom G7 contributed to nearly 10 million active users globally by year‑end 2023. Household BGM meter shipments were around 120 million units annually, making household the leading channel. In the USA, household CGM users numbered over 6 million. The household type benefits from OTC approvals and subscription models priced at 120‑150 pounds per month in the UK. Household segment is expected to maintain dominance in unit share due to consumer wellness adoption.

The household segment is anticipated to reach USD 62,000 million by 2034, growing at a CAGR of 18.5% from USD 12,000 million in 2025, driven by increased adoption of home-based glucose monitoring devices.

Top 5 Major Dominant Countries in the Household Segment

• United States: Projected to grow from USD 3,500 million in 2025 to USD 14,000 million by 2034, with a CAGR of 17.0%.
• China: Expected to increase from USD 2,800 million in 2025 to USD 12,000 million by 2034, at a CAGR of 18.0%.
• India: Forecasted to rise from USD 1,500 million in 2025 to USD 7,500 million by 2034, growing at a CAGR of 19.5%.
• Germany: Anticipated to expand from USD 1,200 million in 2025 to USD 5,000 million by 2034, with a CAGR of 17.0%.
• Brazil: Predicted to grow from USD 900 million in 2025 to USD 4,000 million by 2034, at a CAGR of 17.8%.

Hospital: Hospital and clinical segment accounted for about 30 percent of device units, primarily for inpatient diabetes management and ICU monitoring. Hospitals used CGM systems for ~3 million patients in clinical settings in 2023. BGM meters in hospital use were around 60 million units sold to hospitals yearly. Hospital settings still rely on regulated, prescription‑based CGMs and BGM systems approved for clinical accuracy. Institutional bulk purchasing covers majority of advanced CGMs by Abbott and Dexcom, and trials of Biolinq devices began in hospital settings in early 2024.

The hospital segment is projected to reach USD 45,000 million by 2034, expanding at a CAGR of 16.0% from USD 10,000 million in 2025, due to the increasing demand for advanced glucose monitoring in clinical settings.

Top 5 Major Dominant Countries in the Hospital Segment

• United States: Expected to grow from USD 3,000 million in 2025 to USD 12,000 million by 2034, with a CAGR of 16.0%.
• Germany: Projected to increase from USD 2,000 million in 2025 to USD 8,000 million by 2034, at a CAGR of 16.0%.
• Japan: Anticipated to rise from USD 1,800 million in 2025 to USD 7,200 million by 2034, growing at a CAGR of 16.0%.
• China: Forecasted to expand from USD 1,500 million in 2025 to USD 6,000 million by 2034, with a CAGR of 16.0%.
• France: Predicted to grow from USD 1,200 million in 2025 to USD 4,800 million by 2034, at a CAGR of 16.0%.

Other: Other settings, including pharmacies, point‑of‑care clinics and remote monitoring, accounted for about 10 percent of shipments. Point‑of‑care glucose testing units in the USA numbered 1.05 million in 2024. Other includes wellness clinics and sports facilities deploying CGMs—hundreds of elite athletes used devices in mid‑2024. Biolinq trials in outpatient settings launched in March 2024. Advanced other‑type devices represent innovation and lifestyle use cases beyond diagnosis and insulin management.

The 'Other' segment, encompassing clinics and diagnostic centers, is expected to reach USD 12,163.28 million by 2034, growing at a CAGR of 15.0% from USD 6,568.16 million in 2025.

Top 5 Major Dominant Countries in the Other Segment

• United States: Projected to grow from USD 2,000 million in 2025 to USD 4,000 million by 2034, with a CAGR of 15.0%.
• India: Expected to increase from USD 1,500 million in 2025 to USD 3,000 million by 2034, at a CAGR of 15.0%.
• China: Anticipated to rise from USD 1,200 million in 2025 to USD 2,400 million by 2034, growing at a CAGR of 15.0%.
• Germany: Forecasted to expand from USD 1,000 million in 2025 to USD 2,000 million by 2034, with a CAGR of 15.0%.
• Brazil: Predicted to grow from USD 868.16 million in 2025 to USD 1,763.28 million by 2034, at a CAGR of 15.0%.

BY APPLICATION

Continuous Glucose Monitoring (CGM): CGM application segment represented roughly 40 percent of unit volumes in 2023, that is about 10 million active CGM users globally. Abbott’s Libre system served 6 million users, while Dexcom served just under 3 million, jointly capturing over 80 percent market share in the CGM space. Lifestyle CGM user growth approached 15 percent annually in 2023, especially among non‑diabetic users. The application of CGM extends into wellness, sports, and metabolic health tracking, beyond insulin‑dependent diabetes. CGM applications require sensor replacement every 10‑15 days depending on device (Libre 14 days, Dexcom G7 15 days). CGM applications now include OTC models approved in 2024 for broader consumer access.

The CGM segment is projected to grow from USD 12,000 million in 2025 to USD 47,000 million by 2034, registering a CAGR of 16.0%, driven by technological advancements and increased adoption among diabetic patients.

Top 5 Major Dominant Countries in the CGM Application

• United States: Expected to grow from USD 4,000 million in 2025 to USD 15,000 million by 2034, with a CAGR of 15.5%.
• China: Projected to increase from USD 3,000 million in 2025 to USD 12,000 million by 2034, at a CAGR of 16.0%.
• India: Anticipated to rise from USD 2,000 million in 2025 to USD 8,000 million by 2034, growing at a CAGR of 16.5%.
• Germany: Forecasted to expand from USD 1,500 million in 2025 to USD 6,000 million by 2034, with a CAGR of 16.0%.
• Brazil: Predicted to grow from USD 1,000 million in 2025 to USD 4,000 million by 2034, at a CAGR of 16.0%.

Blood Glucose Meter (BGM): BGM application segment made up approximately 60 percent of overall device unit sales, with around 200 million BGM meters sold globally per year. BGM applications remain dominant in low‑cost, finger‑stick diabetes testing. In markets like USA, retail BGM meter sales exceeded 120 million units per year in 2023. BGM meter application continues to serve first‑line diabetes self‑management where CGM adoption remains low. BGM devices are mostly household and clinical use and require test strips replaced frequently—often hundreds of tests per user annually. BGM application segment remains price‑sensitive and widely accessible.

The BGM segment is expected to increase from USD 16,568.16 million in 2025 to USD 72,163.28 million by 2034, growing at a CAGR of 17.5%, owing to its widespread use and affordability.

Top 5 Major Dominant Countries in the BGM Application

• United States: Projected to grow from USD 5,000 million in 2025 to USD 21,000 million by 2034, with a CAGR of 17.0%.
• India: Expected to increase from USD 3,500 million in 2025 to USD 15,000 million by 2034, at a CAGR of 17.5%.
• China: Anticipated to rise from USD 3,000 million in 2025 to USD 13,000 million by 2034, growing at a CAGR of 17.5%.
• Germany: Forecasted to expand from USD 2,000 million in 2025 to USD 8,500 million by 2034, with a CAGR of 17.0%.
• Brazil: Predicted to grow from USD 1,068.16 million in 2025 to USD 4,663.28 million by 2034, at a CAGR of 17.5%.

BGM and CGM Market Regional Outlook

NORTH AMERICA

North America holds the largest BGM and CGM Market Share regionally. In 2023, North America accounted for over 40 percent of global CGM users. The USA alone had over 6 million Libre users and just under 3 million Dexcom users by early 2024. North America point‑of‑care testing units reached 1.05 million units in 2024. Household CGM deployment in USA households was estimated at ~60 percent of CGM user base. The North America BGM and CGM Market Trends report indicates that FDA clearance for OTC devices in March 2024 immediately expanded accessibility to roughly 200 million eligible adults. Institutional hospital CGM adoption covered millions of inpatient tests, with hospital segment accounting for 30 percent of unit volumes. Regional leadership is driven by regulatory approvals, payer reimbursement policies, and prevalence of diabetes: over 25 million diabetics in USA. Competition among two major companies led to innovation such as Dexcom G7 sensor approved for 15 day wear in April 2025. North America BGM and CGM Market Outlook shows that healthcare providers deployed tens of thousands of CGM units in clinical research settings in 2024. Adoption barriers such as missed smartphone alerts triggered a FDA safety alert in February 2025, prompting software updates across USA device models.

North America's BGM and CGM market is projected to grow from USD 10,000 million in 2025 to USD 40,000 million by 2034, with a CAGR of 16.5%, driven by advanced healthcare infrastructure and high diabetes prevalence.

North America - Major Dominant Countries in the BGM and CGM Market

• United States: Expected to grow from USD 8,000 million in 2025 to USD 32,000 million by 2034, with a CAGR of 16.5%.
• Canada: Projected to increase from USD 1,500 million in 2025 to USD 6,000 million by 2034, at a CAGR of 16.5%.
• Mexico: Anticipated to rise from USD 500 million in 2025 to USD 2,000 million by 2034, growing at a CAGR of 16.5%.
• Cuba: Forecasted to expand from USD 300 million in 2025 to USD 1,200 million by 2034, with a CAGR of 16.5%.
• Dominican Republic: Predicted to grow from USD 200 million in 2025 to USD 800 million by 2034, at a CAGR of 16.5%.

EUROPE

Europe accounted for around 25 percent of global CGM users by end‑2023. In Germany and Austria, CGM adoption among children increased from 3 percent to 16 percent between 2011 and 2016; by 2020 around 370 000 flash‑Glucose users and 96 000 real‑time CGM users were documented. Libre Flash systems covered these volumes. European Libre subscription service in UK priced at 120‑150 pounds per month gained significant traction. The European BGM and CGM Market Analysis indicates that CE‑marked non‑invasive CGMs were approved in 2023, though uptake remained under 1 percent of total users. European hospital systems contributed to approximately 30 percent of CGM clinical use. European sports and wellness adoption included elite athletes using devices at major events in mid‑2024. The Europe BGM and CGM Market Outlook notes that regulatory environment supports reimbursement in national healthcare systems, resulting in steady CGM penetration. BGM meters remained widely used, with BGM application accounting for 60 percent of units across Europe. The European region’s unit shipments included hundreds of thousands of CGM sensors annually in 2023. European market share remains split between Abbott and Dexcom, with Abbott Libre penetrating across more countries. Emerging European startups aim to build non‑invasive CGM products, though their share remains tiny (<1 percent) due to validation lags.

Europe's market is expected to expand from USD 8,000 million in 2025 to USD 32,000 million by 2034, growing at a CAGR of 16.5%, supported by increasing healthcare expenditure and awareness.

Europe - Major Dominant Countries in the BGM and CGM Market

• Germany: Projected to grow from USD 2,500 million in 2025 to USD 10,000 million by 2034, with a CAGR of 16.5%.
• United Kingdom: Expected to increase from USD 2,000 million in 2025 to USD 8,000 million by 2034, at a CAGR of 16.5%.
• France: Anticipated to rise from USD 1,500 million in 2025 to USD 6,000 million by 2034, growing at a CAGR of 16.5%.
• Italy: Forecasted to expand from USD 1,000 million in 2025 to USD 4,000 million by 2034, with a CAGR of 16.5%.
• Spain: Predicted to grow from USD 1,000 million in 2025 to USD 4,000 million by 2034, at a CAGR of 16.5%.

ASIA-PACIFIC

Asia‑Pacific represented approximately 20 percent of global CGM user base by 2023. China, India, Japan and South Korea drove BGM meter volumes—over 50 million BGM units sold annually in Asia‑Pacific. CGM users numbered around 2 million in APAC in 2023. The Asia‑Pacific region’s BGM and CGM Market Trends show increasing adoption in urban healthcare settings, with household CGM user growth accelerating. The APAC segmentation noted hospital CGM installations in major urban hospitals numbered in tens of thousands in 2023. BGM meters dominated unit volumes (about 60 percent share), while CGM grew from negligible share in early 2020s to ~40 percent of new unit sales in 2023 in certain markets. Asia‑Pacific market share saw Dexcom and Abbott initiating local distribution; Abbott Libre reached over 1 million users in China by early 2024. UltraFactory in Bengaluru India expanded production capacity from 10 000 devices monthly to 7× capacity in 2024, enabling tens of thousands of units monthly. Regional policy initiatives improved access in public hospitals. BGM and CGM Market Insights highlight increasing wellness use in urban populations as disposable incomes rise.

Asia’s BGM and CGM market is forecasted to grow from USD 7,000 million in 2025 to USD 30,000 million by 2034, registering a CAGR of 17.5%. This growth is attributed to rising diabetes incidence, increased healthcare access, and growing consumer awareness across emerging economies.

Asia - Major Dominant Countries in the BGM and CGM Market

• China: Projected to expand from USD 2,500 million in 2025 to USD 10,800 million by 2034, at a CAGR of 17.8%, fueled by a large diabetic population and rapid urbanization.
• India: Expected to increase from USD 2,300 million in 2025 to USD 9,900 million by 2034, growing at a CAGR of 17.9%, driven by rising lifestyle diseases and affordable diagnostics.
• Japan: Forecasted to grow from USD 1,500 million in 2025 to USD 6,400 million by 2034, with a CAGR of 17.2%, owing to an aging population and technology adoption.
• South Korea: Anticipated to rise from USD 400 million in 2025 to USD 1,700 million by 2034, registering a CAGR of 17.6%, due to innovation in wearable and continuous monitoring devices.
• Indonesia: Predicted to grow from USD 300 million in 2025 to USD 1,200 million by 2034, at a CAGR of 17.1%, backed by improved healthcare penetration and awareness campaigns.

MIDDLE EAST & AFRICA

Middle East & Africa (MEA) represented around 15 percent of global BGM and CGM device shipments in 2023. BGM meters accounted for the bulk—an estimated 30 million units sold across MEA in 2023. CGM user base numbered approximately 300 000 individuals by end‑2023. Hospital CGM installations were relatively few—hundreds in major UAE and South Africa hospitals. Household CGM users emerged in wealthier MEA urban centers, with subscription models launched in 2023‑2024. The MEA BGM and CGM Market Outlook shows import of Libre and Dexcom sensors increased by 20 percent in 2023. BGM meter dominance remains strong (about 60 percent of unit volumes). Awareness campaigns in Gulf countries boosted diabetic CGM adoption. However, uptake remains low overall; only ~0.5 percent of diabetes patients currently using CGM in MEA. Device costs and regulatory hurdles limit penetration. Recent pilot wellness projects used CGM in Saudi Arabia among athletes and urban users. The MEA region offers opportunity for growth but penetration metrics remain modest.

The Middle East and Africa BGM and CGM market is expected to expand from USD 3,568.16 million in 2025 to USD 17,163.28 million by 2034, growing at a CAGR of 18.7%. Key drivers include healthcare reforms, growing diabetes cases, and government initiatives promoting digital health tools.

Middle East and Africa - Major Dominant Countries in the BGM and CGM Market

• United Arab Emirates: Expected to grow from USD 800 million in 2025 to USD 3,600 million by 2034, with a CAGR of 18.1%, supported by high adoption of digital health solutions.
• Saudi Arabia: Projected to increase from USD 700 million in 2025 to USD 3,200 million by 2034, at a CAGR of 18.6%, driven by public health programs targeting non-communicable diseases.
• South Africa: Anticipated to rise from USD 600 million in 2025 to USD 2,900 million by 2034, growing at a CAGR of 18.9%, due to expanding diagnostic infrastructure.
• Egypt: Forecasted to grow from USD 500 million in 2025 to USD 2,400 million by 2034, with a CAGR of 19.0%, as the country upgrades its chronic disease management systems.
• Nigeria: Predicted to grow from USD 400 million in 2025 to USD 2,063.28 million by 2034, at a CAGR of 19.4%, due to mobile health solutions and increased healthcare investments.

List of Top BGM and CGM Companies

• Abbott
• Dexcom
• Ascensia
• I-SENS
• AgaMatrix
• Osang Healthcare
• Roche
• Senseonics Holdings
• ARKRAY
• Terumo
• Omron
• 77 Elektronika
• Braun
• Acon
• Yuwell
• Sinocare
• Lifescan
• Medtronic
• Yicheng
• SD Biosensor

Top Two Companies with Highest Market Shares

• Abbott – Over 6 million global users of its FreeStyle Libre CGM system, accounting for more than 50% of the global CGM market share.
• Dexcom – Serves just under 3 million users worldwide, holding approximately 30% of the global CGM market share.

Investment Analysis and Opportunities

Investment Analysis and Opportunities in the BGM and CGM Market Report emphasize capital flows and expansion potential. In 2024, Biolinq secured $58 million in venture funding to develop innovative CGM devices with integrated displays and microneedle arrays. The BGM and CGM Market Insights note that startups and biotech firms attracted significant funding as investors seek to challenge the Abbott‑Dexcom duopoly. In 2024, Biolinq began clinical trials, aiming for FDA submission by end‑year. Institutional investment is drawn by the lifestyle CGM opportunity, where adoption has grown nearly 15 percent annually. OTC approvals expanded the addressable US consumer base to over 200 million non‑diabetic adults. Regional manufacturing expansions—such as Ultra human’s Ultra Factory in Bengaluru, growing production to 70 000 devices monthly by 2024—underscore scaling investment. Investment opportunities include manufacturing capacity expansion across Asia‑Pacific, where over 50 million BGM units are sold annually. Government procurement for hospital CGM systems, particularly in North America (USA hospital installations numbering in millions) and Europe (Germany registers showing 370 000 flash‑users + 96 000 trig users), creates further demand. The BGM and CGM Industry Report highlights unmet needs in non‑invasive detection segments, where CE‑marked systems remain under 1 percent market share, presenting technical R&D investment opportunities. Lastly, integration with health data platforms and sports/wellness apps represents growth potential, as seen in athlete usage at mid‑2024 Olympic training and consumer uptake in lifestyle markets.

New Product Development

New Product Development in the BGM and CGM Market Insights emphasizes device innovation and usability enhancements. Dexcom launched its G7 15‑day sensor, cleared by the FDA in April 2025, permitting longer wear duration and improved convenience. Abbott rolled out two new CGM models—Libre Rio for non‑insulin type‑2 users and Lingo for non‑diabetic metabolism tracking—in USA in mid‑2024 after UK launch in early 2024; these products use sensor wear durations up to 14 days and subscription pricing in the range of 120‑150 pounds per month. Biolinq’s system under development uses seven silicon microneedles with an onboard color display to deliver glucose status without needing a smartphone. Ultrahuman expanded manufacturing to produce up to 70 000 devices monthly in Bengaluru by 2024. Non‑invasive CGMs received CE marks in Europe in 2023; though uptake remains under 1 percent, development continues. Dexcom is targeting improved battery life and direct Apple Watch integration—its G7 now connects to Apple Watch in the USA. Abbott’s FreeStyle Libre 3, cleared in May 2022, provides one‑hour warm‑up time and accurate measurements without fingerstick calibration. Sensor wear maximized at 14 days, Libre 3 also supports alerts configuration. These developments reflect a push for longer wear, user comfort, non‑invasive detection, smartphone‑free reading and integration with wellness platforms.

Five Recent Developments

• In April 2025, Dexcom obtained FDA clearance for its G7 15‑day sensor, enabling users to wear sensors up to 15 days without replacement.
• In March–June 2024, Abbott received FDA clearance for Libre Rio (for non‑insulin diabetes users) and Lingo (for non‑diabetic metabolic tracking), expanding access to over 200 million US adults.
• In mid‑2024, Biolinq raised $58 million in venture capital to develop a CGM with onboard display using seven microneedles, targeting type‑2 users.
• In 2023, non‑invasive CGM systems received CE marks in Europe, though adoption remained below 1 percent of sensor users.
• In 2024, Ultrahuman expanded its Bengaluru UltraFactory production from 10 000 devices monthly (2022) to a 7× increase, reaching about 70 000 devices monthly.

Report Coverage of BGM and CGM Market

The BGM and CGM Market Report scope includes global and regional market sizing, segmentation by type and application, competitive landscape, and recent developments. Coverage includes global CGM user base metrics (approx. 10 million users in 2023), BGM meter annual shipments (200 million units), and diabetes population figures (400 million individuals in 2024). Included are US‑specific metrics: 6 million Libre users, 3 million Dexcom users, 1.05 million point‑of‑care glucose testing units in 2024, and 25 million eligible diabetics. The report also covers detailed segmentation: household (60 percent of units), hospital (30 percent), and other (10 percent) channels. Application division between CGM (40 percent units) and BGM (~60 percent units) is provided. Geographic coverage spans North America, Europe, Asia‑Pacific, Middle East & Africa, with share figures (North America ~40 percent CGM users, Europe ~25 percent, APAC ~20 percent, MEA ~15 percent). Company profiles include Abbott (6 million users, >5 

BGM and CGM Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 33481.89 Million in 2026
Market Size Value By	USD 139659.37 Million by 2035
Growth Rate	CAGR of 17.2% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Continuous Glucose Monitoring (CGM) Blood Glucose Meter (BGM) By Application : Household Hospital Other
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample